New vaccine aims to stop lung cancer recurrence in High-Risk patients
NCT ID NCT05642195
First seen Sep 30, 2025 · Last updated May 06, 2026 · Updated 32 times
Summary
This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), to see if it can stop non-small cell lung cancer from returning after surgery. About 30 adults with no signs of cancer after surgery will receive the vaccine and N-803 injections over six months. The goal is to train the immune system to recognize and attack any remaining cancer cells, potentially preventing relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.